Daiichi Sankyo Company, Limited

Daiichi Sankyo Europe Gmbh

Amgen Inc.

Kinki University

U3 Pharma Gmbh

Sabine Blum

Matthias Schneider

Xiaoping Jin

Robert Allen Beckman

Renee Jeanne Mendell-Harary

Daniel Freeman

Thore Hettmann

Reimar Abraham

Suguru Ueno

Kazuhiko Nakagawa

Kimio Yonesaka

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

Nucleic acid biomarker and use thereof

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.

Protein biomarker and uses thereof

To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; or -L-L-L- (the anti-HER3 antibody is connected to the terminal of L, the antitumor compound is connected to the carbonyl group of &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety or the C terminal of L, with the nitrogen atom of the amino group at position 1 as a connecting position). 

Anti-HER3 antibody-drug conjugate

Growing community of inventors

Munich, Germany

Sabine Blum